MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1

Kunio Iura, Kenichi Kouhashi, Takeaki Ishii, Akira Maekawa, Hirofumi Bekki, Hiroshi Otsuka, Yuichi Yamada, Hidetaka Yamamoto, Yoshihiro Matsumoto, Yukihide Iwamoto, Yoshinao Oda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2% of synovial sarcomas, 67.7% of myxoid liposarcomas, 43.8% of osteosarcomas, 41.4% of angiosarcomas, 24.6% of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4% of chondrosarcomas. NY-ESO-1 expression was found in 88.2% of myxoid liposarcomas, 61.1% of synovial sarcomas, 31.3% of osteosarcomas, 21.4% of pleomorphic liposarcomas, 16.7% of desmoplastic small round cell tumors, and 14.3% of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.

Original languageEnglish
Pages (from-to)383-392
Number of pages10
JournalVirchows Archiv
Volume471
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Immunotherapy
Synovial Sarcoma
Bone and Bones
Testicular Neoplasms
Myxoid Liposarcoma
Neoplasms
Chondrosarcoma
Osteosarcoma
Antigens
Testis
Desmoplastic Small Round Cell Tumor
Liposarcoma
Hemangiosarcoma
Neurilemmoma
Immunohistochemistry
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

MAGEA4 expression in bone and soft tissue tumors : its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1. / Iura, Kunio; Kouhashi, Kenichi; Ishii, Takeaki; Maekawa, Akira; Bekki, Hirofumi; Otsuka, Hiroshi; Yamada, Yuichi; Yamamoto, Hidetaka; Matsumoto, Yoshihiro; Iwamoto, Yukihide; Oda, Yoshinao.

In: Virchows Archiv, Vol. 471, No. 3, 01.09.2017, p. 383-392.

Research output: Contribution to journalArticle

@article{688eaa1a298f4a8f92721700a3ae036d,
title = "MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1",
abstract = "Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2{\%} of synovial sarcomas, 67.7{\%} of myxoid liposarcomas, 43.8{\%} of osteosarcomas, 41.4{\%} of angiosarcomas, 24.6{\%} of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4{\%} of chondrosarcomas. NY-ESO-1 expression was found in 88.2{\%} of myxoid liposarcomas, 61.1{\%} of synovial sarcomas, 31.3{\%} of osteosarcomas, 21.4{\%} of pleomorphic liposarcomas, 16.7{\%} of desmoplastic small round cell tumors, and 14.3{\%} of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.",
author = "Kunio Iura and Kenichi Kouhashi and Takeaki Ishii and Akira Maekawa and Hirofumi Bekki and Hiroshi Otsuka and Yuichi Yamada and Hidetaka Yamamoto and Yoshihiro Matsumoto and Yukihide Iwamoto and Yoshinao Oda",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s00428-017-2206-z",
language = "English",
volume = "471",
pages = "383--392",
journal = "Virchows Archiv",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - MAGEA4 expression in bone and soft tissue tumors

T2 - its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1

AU - Iura, Kunio

AU - Kouhashi, Kenichi

AU - Ishii, Takeaki

AU - Maekawa, Akira

AU - Bekki, Hirofumi

AU - Otsuka, Hiroshi

AU - Yamada, Yuichi

AU - Yamamoto, Hidetaka

AU - Matsumoto, Yoshihiro

AU - Iwamoto, Yukihide

AU - Oda, Yoshinao

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2% of synovial sarcomas, 67.7% of myxoid liposarcomas, 43.8% of osteosarcomas, 41.4% of angiosarcomas, 24.6% of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4% of chondrosarcomas. NY-ESO-1 expression was found in 88.2% of myxoid liposarcomas, 61.1% of synovial sarcomas, 31.3% of osteosarcomas, 21.4% of pleomorphic liposarcomas, 16.7% of desmoplastic small round cell tumors, and 14.3% of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.

AB - Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2% of synovial sarcomas, 67.7% of myxoid liposarcomas, 43.8% of osteosarcomas, 41.4% of angiosarcomas, 24.6% of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4% of chondrosarcomas. NY-ESO-1 expression was found in 88.2% of myxoid liposarcomas, 61.1% of synovial sarcomas, 31.3% of osteosarcomas, 21.4% of pleomorphic liposarcomas, 16.7% of desmoplastic small round cell tumors, and 14.3% of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.

UR - http://www.scopus.com/inward/record.url?scp=85025804233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025804233&partnerID=8YFLogxK

U2 - 10.1007/s00428-017-2206-z

DO - 10.1007/s00428-017-2206-z

M3 - Article

C2 - 28744588

AN - SCOPUS:85025804233

VL - 471

SP - 383

EP - 392

JO - Virchows Archiv

JF - Virchows Archiv

SN - 0945-6317

IS - 3

ER -